StockData
Actuate Therapeutics, Inc. logo

Actuate Therapeutics, Inc. (ACTU) stock

ACTUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 0/30
$0.25−0.02 (-6.12%)

Close on Nov 17, 2026Market cap $6.04MP/E –Yield –

Actuate Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Actuate Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $8.57M, down 27.6% year over year. For fiscal 2025 it was $10.29M, down 44.9% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$10.29M-44.9%
FY2024Dec 31, 2024$18.68M-14.0%
FY2023Dec 31, 2023$21.71M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.81M-16.8%
Q2 FY2026Jun 30, 2026$2.07M-25.2%
Q1 FY2026Mar 31, 2026$2.57M-20.3%
Q4 FY2025Dec 31, 2025$2.13M-42.2%
Q3 FY2025Sep 30, 2025$2.18M-42.0%
Q2 FY2025Jun 30, 2025$2.76M-36.8%
Q1 FY2025Mar 31, 2025$3.22M-53.1%
Q4 FY2024Dec 31, 2024$3.69M-44.5%
Q3 FY2024Sep 30, 2024$3.76M-34.8%
Q2 FY2024Jun 30, 2024$4.37M-8.5%
Q1 FY2024Mar 31, 2024$6.86M–
Q4 FY2023Dec 31, 2023$6.65M–
Q3 FY2023Sep 30, 2023$5.76M–
Q2 FY2023Jun 30, 2023$4.78M–

More Actuate Therapeutics figures

See a number that looks wrong?